Empagliflozin Improves Muscle Weakness in a Patient with Suspected Glycogen Storage Myopathy: A Case Report
This case report describes a patient with suspected glycogen storage myopathy who experienced significant clinical improvement in muscle weakness and metabolic parameters after three months of empagliflozin treatment, suggesting a potential therapeutic role for the drug that warrants further investigation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Muscles are the engines that power every movement we make, from lifting a cup to climbing a flight of stairs. To keep these engines running smoothly, our bodies rely on a delicate balance of energy storage and release. One of the primary ways the body stores energy is by packing it away as glycogen, a substance similar to a tightly wound spring that muscles can unspool when they need to move. In rare metabolic disorders, the machinery that breaks down this stored energy malfunctions. Instead of being used, the glycogen builds up inside the muscle fibers like debris clogging a machine, causing them to swell, weaken, and eventually fail. This condition, known as glycogen storage myopathy, leaves patients with progressive weakness, difficulty breathing when lying flat, and an inability to sustain physical activity. For decades, doctors have had few tools to treat this specific problem, often relying on general supportive care that does not address the root cause of the accumulated energy stores.
A recent case report from researchers at Capital Medical University Yanjing College tells the story of a young man who faced this exact struggle and found unexpected relief through a medication not originally designed for muscle disease. The patient had suffered for six months with worsening weakness in his hips and shoulders, making it hard to climb stairs or lift objects. His condition followed a frustrating pattern: he felt slightly better in the morning but grew increasingly exhausted and short of breath as the day went on. Standard tests ruled out common causes like nerve disorders or autoimmune diseases, but a deep look at a small sample of his muscle tissue revealed the true culprit. Under a powerful microscope, the muscle cells were packed with massive amounts of glycogen, confirming that his muscles were essentially drowning in their own stored energy. Despite trying various nutritional supplements and standard treatments, his condition did not improve.
The medical team then decided to try a different approach, turning to a drug called empagliflozin. This medication is typically prescribed to help people with diabetes lower their blood sugar by encouraging the kidneys to release excess glucose into the urine. The logic behind using it for this muscle condition was speculative but intriguing: if the drug lowers the amount of sugar available in the blood, it might also reduce the flow of sugar into the muscle cells, potentially slowing down the production of new glycogen and allowing the body to burn off the excess that was already there. The patient began taking a small daily dose of 10 milligrams. Over the next three months, the transformation was striking. His muscle strength, which had been rated at a level where he could only move his limbs against gravity with great effort, returned to full normal strength. He could once again climb stairs and lift heavy objects without difficulty. The shortness of breath that had plagued him when lying down vanished completely.
Beyond the physical recovery, the numbers in his blood told a matching story of healing. Before the treatment, a key marker of muscle damage called creatine kinase was elevated to 856 units per liter, far above the normal limit of 310. After three months, this number dropped to 142, settling well within the healthy range. His liver function tests, which had also been abnormal, returned to normal levels. Throughout this period, his blood sugar remained stable, hovering between 4.2 and 5.6 millimoles per liter, with no episodes of dangerously low sugar or other side effects. The researchers noted that the electrical signals from his muscles, which had previously shown signs of distress, began to look much more like a healthy pattern.
The author of the report are careful to state that this is a single story, not a final proof that the drug works for everyone with this condition. They describe the findings as a strong hint that warrants further investigation rather than a solved mystery. It is possible that the improvement was due to other factors or simply a natural fluctuation in the disease, though the timing of the recovery strongly points to the medication. The team acknowledges that they did not take a second muscle biopsy to visually confirm that the glycogen had physically disappeared, relying instead on the patient's return to normal life and the improvement in blood markers. Nevertheless, the case offers a promising new direction. It suggests that a drug already known for its safety and ease of use might be able to help muscles clear out their energy blockages, offering hope for a condition that currently has very few effective treatments.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.